ADHD in Women: Why Menopause Changes Everything
Draft for review only — not for publication or scheduling
If you have reached midlife and suddenly feel that your usual systems no longer work, you are not imagining it. Menopause does not create ADHD, but hormonal transition can expose or intensify executive-function difficulties that you have spent years compensating for.
The “masking debt” of midlife
For many women, ADHD has been hidden in plain sight.
You may have achieved highly, arrived early, over-prepared, copied other people’s organisational systems or built a life around urgency. Perhaps perfectionism became your unofficial treatment plan. Perhaps anxiety kept you moving when motivation would not.
These strategies can work, until the demands on your attention, memory and emotional regulation exceed the capacity of your carefully constructed system.
I call this masking debt: the accumulated physical and psychological cost of appearing organised while privately spending enormous energy to remain afloat. It is my own descriptive term rather than an established clinical construct, but it names something many women recognise immediately.
ADHD is a neurodevelopmental condition, meaning that its underlying traits begin in childhood, even if they are not recognised until adulthood. Girls and women may be missed because difficulties are more internalised, inattentive or masked, while anxiety, depression and exhaustion receive the clinical attention first (Hinshaw et al., 2022; Kooij et al., 2025).
Then perimenopause arrives. Sleep may become fragmented. Hot flushes can interrupt concentration. Mood becomes less predictable. Working memory feels less available.
The brain’s operating system has not necessarily changed into something unrecognisable. Rather, the compensatory software may no longer be sufficient.
What changes during perimenopause and menopause?
Perimenopause is the transitional phase before menopause, during which periods may become irregular and symptoms can fluctuate. Menopause is reached when you have not had a period for 12 months; the years afterwards are described as postmenopause. The NHS describes these as a natural part of life caused by falling hormone levels, and notes that perimenopausal symptoms commonly last around seven to nine years, though experience varies widely from person to person.
Source: NHS menopause and perimenopause symptoms.
Common experiences can include:
Brain fog and forgetfulness
Problems with memory or concentration
Difficulty initiating or completing tasks
Sleep disruption and night sweats
Anxiety, irritability or low mood
Emotional reactivity
Reduced tolerance for noise, demands or interruptions
Feeling overwhelmed by previously manageable responsibilities
These experiences overlap substantially with ADHD. That overlap can be confusing and invalidating. You may hear, “It is just menopause,” when you recognise a lifelong pattern. Conversely, you may assume you have ADHD when the primary difficulty is a new menopause-related cognitive change, a sleep disorder, depression, anxiety or another physical-health issue.
Both possibilities deserve careful attention.
What does the current evidence show?
The strongest evidence to date comes from a population-based Icelandic cohort study published in 2025. Researchers followed 5,392 women aged 35 to 55, of whom 535 had ADHD, and compared perimenopausal symptom burden at baseline and five-year follow-up.
Women with ADHD reported markedly higher symptom burden across every domain measured. Severe symptoms overall were reported by 54.2% of women with ADHD compared with 30.1% of women without. The gap held for psychological symptoms (58.6% versus 36.0%), somatic symptoms (30.4% versus 13.9%) and urogenital symptoms (43.2% versus 27.5%). Peak symptom severity also arrived earlier in the ADHD group, at ages 35 to 39 rather than 45 to 49 (Jakobsdóttir Smári et al., 2025).
That earlier peak matters clinically. It suggests that women with ADHD may be experiencing perimenopausal change at an age when neither they nor their clinicians are looking for it.
A separate Irish cross-sectional study published in 2026 examined 602 women: 377 in an ADHD group and 225 without ADHD. The ADHD group included people with a formal diagnosis or self-identification who also met the study’s ADHD screening criteria. Participants completed measures relating to premenstrual symptoms, postpartum depression and climacteric symptoms.
The ADHD group reported more menstrual irregularity, more severe premenstrual symptoms, higher retrospective postpartum-depression scores and more severe peri- and post-menopausal symptoms (Boyd et al., 2026).
That study cannot establish that ADHD caused these outcomes. It relied substantially on self-report and retrospective recall, did not use clinical diagnostic interviews, and the peri- and post-menopause groups were not fully age-matched. Medication differences and the absence of race, ethnicity and socioeconomic data also limit how widely the results can be applied.
The significance is therefore not “all women with ADHD will struggle with menopause”. The more responsible conclusion is that reproductive stage may be clinically relevant when understanding changes in attention, mood, sleep and daily functioning, and that this is now supported by more than self-report alone.
Lifelong ADHD, menopause-related change, or both?
This is not a diagnostic checklist. It is a map for a better conversation.
Three patterns are worth distinguishing, and they are not mutually exclusive.
A lifelong pattern newly exposed. The difficulties are recognisable from childhood and adolescence, even if they were mild, well-compensated or attributed to something else. School reports, old friendships and family memories usually carry traces. What is new is not the trait but the failure of the strategy.
A genuinely new change. Attention, memory and mood shifted in midlife with no meaningful childhood precursor. Here the more likely explanations include menopause-related cognitive change, sleep disruption, depression, anxiety, thyroid disease, anaemia or another physical-health factor.
Both at once. A lifelong neurodevelopmental profile meets a changing hormonal landscape and years of accumulated masking debt. This is common, and it is the pattern most often missed, because each explanation is treated as though it disproves the other.
A midlife assessment should explore when the pattern began, where it appears, how severe the impairment is and what else might explain it. In practice, that means examining:
Childhood history: school reports, memories, unfinished tasks, daydreaming, impulsivity or chronic disorganisation.
Persistence across settings: home, education, employment, relationships and self-care.
Functional impairment: missed deadlines, financial administration, household tasks, emotional conflict or exhaustion.
Sleep and physical health: insomnia, night sweats, sleep apnoea, thyroid conditions, anaemia and other relevant factors.
Mood and anxiety: depression and anxiety can both mimic and amplify executive dysfunction.
Medication and substance use: including prescribed ADHD medication, antidepressants, caffeine and alcohol.
Menstrual and menopause history: including cycle changes, symptom timing and any surgical or treatment-related menopause.
You should not be diagnosed from an article, an online quiz or a single symptom. A screening tool can begin a conversation, but assessment requires clinical judgement.
Why sleep and emotional regulation matter
Executive function is not an isolated mental faculty. It is affected by the body’s wider state.
A night of disrupted sleep can reduce attention, working memory and emotional inhibition the following day. Repeated nights of poor sleep can create a bone-deep depletion that resembles, and magnifies, ADHD. Meanwhile, anxiety can consume attentional resources, leaving less capacity for planning and flexible thinking.
This is why a compassionate assessment does not ask only, “Do you forget things?” It also asks:
Are you sleeping?
Are you waking hot or distressed?
Are you recovering between demands?
Are you experiencing persistent low mood?
Are you carrying years of compensatory strain?
Do your emotional reactions feel faster or more intense than before?
What about medication?
A 2026 narrative review by Wynchank and Kooij sets out the position plainly: there are no randomised controlled trials of ADHD medication specific to perimenopausal or post-menopausal women. Clinical decisions therefore rest on individual assessment, extrapolation from younger cohorts, expert consensus and small observational studies.
Menopausal hormone therapy is not established as a treatment for ADHD, and there is no guarantee that it will improve attention or executive functioning. The review does, however, describe it as a possible adjunctive strategy: by easing vasomotor symptoms, sleep disruption and mood disturbance, hormone therapy may indirectly reduce the load on daytime attention and executive function. That is a different claim from treating the ADHD itself, and it is a decision for a qualified prescriber.
Equally, you should not assume that ADHD medication must automatically be increased because you are perimenopausal. The same authors favour individualised, sequenced treatment over routine dose adjustment.
Do not alter stimulant, non-stimulant or hormone medication without discussing it with your prescribing clinician. Cardiovascular health, blood pressure, pulse, sleep, mood and other conditions all matter.
The wider reproductive lifespan
The interaction between ADHD and reproductive stages may begin long before menopause.
Some women notice premenstrual changes in attention, irritability, energy or emotional regulation. Boyd et al. (2026) found more severe premenstrual symptoms in the ADHD group, although the study design cannot determine why. There is preliminary clinical interest in whether stimulant dosage might be adjusted across the menstrual cycle for some women, but this remains an area of active investigation rather than established practice (de Jong et al., 2023).
Pregnancy and the postpartum period can also place considerable pressure on executive functioning. Sleep deprivation, changing responsibilities, reduced support and mood vulnerability may combine into an intense psychological load. The same 2026 study found higher retrospective postpartum-depression scores in its ADHD group. That should be read as an association within a self-report study, not as proof that ADHD causes postpartum depression.
A lifespan perspective matters because your current experience may be part of a longer pattern, or it may be a genuinely new change. Good care makes room for both.
A practical framework: Name, Normalise, Redirect
Name–Normalise–Redirect is Dr Danielle’s own reflective and communication framework. It is not an established treatment protocol or a validated clinical intervention.
Use it as a gentle way to move from shame towards useful action.
Name. “I am experiencing brain fog, task-initiation difficulty and stronger emotional reactions.”
Normalise. “These symptoms can occur in ADHD, menopause, sleep disruption, anxiety and depression. They are not evidence that I am lazy or failing.”
Redirect. “I will track the pattern and discuss it with my GP or a qualified ADHD- and menopause-informed clinician.”
What you can do next
For the next few weeks, consider recording:
Sleep quality and night-time waking
Hot flushes or night sweats
Mood, anxiety and irritability
Attention, memory and task initiation
Menstrual or menopause-related changes
Medication timing, benefits and side effects
The practical impact on work, relationships and daily living
Also write down childhood examples before an assessment. You do not need a perfect archive of your past. A few concrete memories, school comments or conversations with relatives may help establish whether difficulties were lifelong.
You can begin by speaking with your NHS GP, who can discuss menopause symptoms, mental health, physical-health factors and appropriate onward support. You may also wish to explore Life Changes 4 Good neurodiversity resources and psychological therapy services.
When urgent support is needed
If low mood becomes overwhelming, or you are thinking about harming yourself or someone else:
Call 999 or go to A&E if there is immediate danger.
In England, contact NHS 111 for urgent mental-health support; the option number is to be confirmed by Dr Danielle before publication.
Contact Samaritans for urgent emotional support; the telephone number is to be confirmed by Dr Danielle before publication.
Parents and carers can contact the YoungMinds Parents Helpline; telephone, opening-hour and email details are to be confirmed by Dr Danielle before publication.
A compassionate final note
You are not required to choose between “ADHD” and “menopause” as though one explanation must cancel out the other.
Your experience may be layered. A lifelong neurodevelopmental profile may meet a changing hormonal and physical landscape, while years of masking and over-functioning finally become unsustainable. That is not a character flaw. It is information.
The aim is not intensity. It is consistency: one careful observation, one honest conversation and one supportive adjustment at a time.
You deserve care that sees the whole tapestry: your history, body, brain, relationships and hopes for the future.
Educational disclaimer
This article is for general educational purposes only. It does not provide a diagnosis, medical advice or individual treatment recommendations. Please consult your GP, prescribing clinician or another appropriately qualified healthcare professional about your circumstances.
References
Boyd, C., Wrigley, M., Kilbride, K., Mulligan, A., & Bramham, J. (2026). ADHD and the female reproductive stages: Menstruation, perinatal and menopause. Archives of Women’s Mental Health, 29(3), Article 89. https://doi.org/10.1007/s00737-026-01718-x
de Jong, M., Wynchank, D. S. M. R., van Andel, E., Beekman, A. T. F., & Kooij, J. J. S. (2023). Female-specific pharmacotherapy in ADHD: Premenstrual adjustment of psychostimulant dosage. Frontiers in Psychiatry, 14, Article 1306194. https://doi.org/10.3389/fpsyt.2023.1306194
Hinshaw, S. P., Nguyen, P. T., O’Grady, S. M., & Rosenthal, E. A. (2022). Annual research review: Attention-deficit/hyperactivity disorder in girls and women: Underrepresentation, longitudinal processes, and key directions. Journal of Child Psychology and Psychiatry, 63(4), 484–496. https://doi.org/10.1111/jcpp.13480
Jakobsdóttir Smári, U., Valdimarsdóttir, U. A., Wynchank, D., de Jong, M., Aspelund, T., Hauksdóttir, A., Thordardóttir, E. B., Tómasson, G., Jakobsdóttir, J., Lu, D., Nevriana, A., Larsson, H., Kooij, J. J. S., & Zoëga, H. (2025). Perimenopausal symptoms in women with and without ADHD: A population-based cohort study. European Psychiatry, 68(1), Article e133. https://doi.org/10.1192/j.eurpsy.2025.10101
Kooij, J. J. S., de Jong, M., Agnew-Blais, J., Amoretti, S., Bang Madsen, K., Barclay, I., Bölte, S., Borg Skoglund, C., Broughton, T., Carucci, S., van Dijken, D. K. E., Ernst, J., French, B., Frick, M. A., Galera, C., Groenman, A. P., Kopp Kallner, H., Kerner auch Koerner, J., Kittel-Schneider, S., ... Wynchank, D. (2025). Research advances and future directions in female ADHD: The lifelong interplay of hormonal fluctuations with mood, cognition, and disease. Frontiers in Global Women’s Health, 6, Article 1613628. https://doi.org/10.3389/fgwh.2025.1613628
Wynchank, D., & Kooij, J. J. S. (2026). Pharmacological management of ADHD in women across perimenopause, menopause and post-menopause. Drugs & Aging, 43(5), 385–395. https://doi.org/10.1007/s40266-026-01291-z
Dr Danielle Baillieu | Chartered Counselling Psychologist
Website: lifechanges4good.com | Email: dr.danielle@Lifechanges4good.com
Comments